PCR-Based POC Molecular Diagnostic System to Combat Infectious Diseases

Chlamydia, Gonorrhea, and Trichomoniasis are among the most common sexually transmitted infections (STIs) worldwide, with an estimated 129 million, 82 million, and 151 million cases respectively reported in 2020. Detecting these infections accurately typically relies on PCR-based molecular diagnostics, which have traditionally been carried out in centralized laboratories that require significant infrastructure. This setup limits accessibility in low- and middle-income countries where medical resources are often scarce. Now, a point-of-care (POC) molecular diagnostic device integrates all processes into a single, compact instrument to provide a rapid, reliable solution for detecting STIs, enabling timely interventions in resource-constrained settings.

Kryptos Biotechnologies (Hayward, CA, USA) is advancing its proprietary PCR-based POC molecular diagnostic system, the KUICK System, designed to combat infectious diseases and enhance healthcare outcomes globally. Kryptos is collaborating with Osang Healthcare (Gyeonggi-do, Republic of Korea) for a research project that will focus on developing molecular diagnostic reagents for STIs. The aim of this collaboration is to create a multiplex STI diagnostic test capable of detecting Chlamydia, Gonorrhea, and Trichomoniasis in under 30 minutes from a single patient sample.

As part of this collaboration, Osang will develop real-time PCR reagents, while Kryptos will focus on optimizing the KUICK System, particularly its innovative cartridge with integrated sample preparation chemistries. The system’s performance is also being improved to ensure reliability in diverse healthcare settings. In developed countries, the device will allow smaller clinics to offer accurate, same-day results, thereby significantly improving patient care.

“Our proprietary photothermal heating technology enables the KUICK System to meet diverse market demands for speed, accuracy, cost-efficiency, and portability,” said Dr. Jun Ho Son, CTO of Kryptos Biotechnologies and principal investigator of the project. “We are committed to ensuring this product makes a meaningful impact on healthcare environments, particularly in low- and middle-income countries.”

Related Links:
Kryptos Biotechnologies 
Osang Healthcare

Visit expo >

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

Gold Member

Fully Automated Cell Density/Viability Analyzer

BioProfile FAST CDV

New

HSV-1 Test

Herpes Simplex Virus 1 Test

New

PROM Test

AMNIOQUICK DUO